

19258CC

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc. 10/05/2001

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE**STATEMENT BY APPLICANT**

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	09/835,699
Filing Date	April 16, 2001
First Named Inventor	Armstrong, et al.
Group Art Unit	1631
Examiner Name	Martinell, James
Attorney Docket Number	19258CC

Sheet	2	of	4
-------	---	----	---

OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
L	AG 8	Gallichan, W. et al. "Mucosal Immunity and Protection after Intranasal Immunization with Recombinant Adenovirus Expressing Herpes Simplex Virus Glycoprotein B". The Journal of Infe. Disease 1993, Vol. 168, PP. 622-629.
L	AH 5	Byars et al. "Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection"; Vaccine 1994, Vol. 12, No. 3, PP. 200-209.
L	AI 4	Straus et al. "Induction and Enhancement of Immune Responses to Herpes Simplex Virus Type 2 in Humans by Use of a Recombinant Glycoprotein D Vaccine", J. of Infectious Diseases, Vol 167, PP. 1045-52 (1993).
L	AJ 4	Ghiasi et al. "Expression of Seven Herpes Simplex Virus Type 1 Glycoproteins (gB, gC, gD, gE, gG, gH and gI): Comparative Protection against Lethal Challenge in Mice"; J. Virology, Apr 1994, PP. 2118-2126.
L	AK 5	Wachsman et al. "Protection from herpes simplex virus type 2 is associated with T cells involved in delayed type hypersensitivity that recognize glycosylation-related epitopes in glycoprotein D", Vaccine, Vol. 10, No. 7, PP. 447-454. (1992)
L	AL 4	Ghiasi et al. "Immunoselection of recombinant baculoviruses expressing high levels of biologically active herpes simplex virus type 1 glycoprotein D", Arch. Virol (1991) 121: 163-178.
L	AM 4	Burke, "Current developments in herpes simplex virus vaccines", Virology, Vol. 4, 1993, PP. 187-197.
L	AN 4	Burke, "Development of a Herpes Simplex Virus Subunit Glycoprotein Vaccine for Prophylactic and Therapeutic Use", Reviews of Infectious Diseases, Vol. 13, Suppl 11, P S906-S911 (1991).
L	AO 8	Lasky, "From Virus to Vaccine: Recombinant Mammalian Cell Lines as Substrates for the Production of Herpes Simplex Virus Vaccines", J. of Med. Virology, 31: PP. 59-61 (1990).
L	AP 4	Aurelian et al. "Immune Responses to Herpes Simplex Virus in Guinea Pigs (Footpad Model) and Mice Immunized with Vaccinia Virus Recombinants Containing Herpes Simplex Virus Glycoprotein D", Review of Infec. Diseases, Vol. 13, (Suppl 11) S924-934 (1991).
L	AQ 4	Rooney et al. "Live Vaccinia Virus Recombinants Expressing Herpes Simplex Virus Genes", Reveiws of Infec. Diseases, Vol. 13 (Suppl 11) p S898-903 (1991).
L	AR 4	Ritchie et al. "Passive Transfer of Anti-Herpes Simplex Virus Type 2 Monoclonal and Polyclonal Antibodies Protect Against Herpes Simplex Virus Type 1-induced but not Herpes Simplex Virus Type 2-induced Stromal Keratitis", Invest. Ophthal & Vis. Science, Vol. 34, No. 8, PP. 2460-2468 (1993).
L	AS 4	Montgomery et al. "Heterologous and Homologous Protection Against Influenza A by DNA vaccination: Optimization of DNA Vectors", DNA and CELL BIOLOGY, Vol. 12, No. 9, PP. 777-783 (1993).
L	AT 4	Ulmer et al. "Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein", Science, Vol. 259, PP. 1745-1749 (1993).
L	AU 4	Browne et al. "Analysis of protective immune responses to the glycoprotein H-glycoprotein L complex of herpes simplex virus-type 1", J. of Gen. Virology, Vo. 74, PP. 2813-2817 (1993).

Examiner Signature	<i>[Signature]</i>	Date Considered	6/24/03
--------------------	--------------------	-----------------	---------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE**STATEMENT BY APPLICANT**

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	09/835,699
Filing Date	April 16, 2001
First Named Inventor	Armstrong, et al.
Group Art Unit	1631
Examiner Name	Martinell, James
Attorney Docket Number	19258CC

Sheet

3

of

4

OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
<i>L</i>	<i>AV</i>	Stanberry et al. "Vaccination with Recombinant Herpes Simplex Virus Glycoproteins: Protection Against Initial and Recurrent Genital Herpes", Jour. of Infect. Dis., Vol. 155, No. 5, PP. 914-920 (1987).
<i>L</i>	<i>AW</i>	Eisenberg et al. "Synthetic Glycoprotein D-related Peptides Protect Mice against Herpes Simplex Virus Challenge", J. of Virology, Vol. 56, No. 3, PP. 1014-1017 (1985).
<i>L</i>	<i>AX</i>	Long et al. "Glycoprotein D Protects Mice Against Lethal Challenge with Herpes Simplex Virus Types 1 and 2", Infect. and Immunity, Vol. 37, No. 2, PP. 761-764 (1984).
<i>L</i>	<i>AY</i>	Dix et al. "Use of Monoclonal Antibody Directed Against Herpes Simplex Virus Glycoprotein to Protect Mice Against Acute Virus-Induced Neurological Disease", Infection and Immunity, Vol. 34, No. 1, PP. 192-199 (1981).
<i>L</i>	<i>AZ</i>	Stanberry et al. "Herpes simplex virus glycoprotein immunotherapy of recurrent genital herpes: factors influencing efficacy", Antiviral Res. Vol. 11, PP. 203-214 (1989).
<i>L</i>	<i>AA</i>	Kino et al. "Immunogenicity of herpes simplex virus glycoprotein gB-1 related protein produced in yeast", Chemo-Sero-Ther. Res. Inst. Japan (1988).
<i>L</i>	<i>AAB</i>	McDermott et al. "Protection of Mice against Lethal Challenge with Herpes Simplex Virus...Expressing HSV Glycoprotein B", Virology, Vol. 169, PP. 244-247 (1989).
<i>L</i>	<i>AAC</i>	Schmid et al. "The Role of T cell Immunity in Control of Herpes Simplex Virus", Current Topics in Microbiology and Immunology, Vol. 179, PP. 57-74 (1992).
<i>L</i>	<i>AAB</i>	Banks et al. "Recognition by and in Vitro Induction of Cytotoxic T Lymphocytes against Predicted Epitopes of the Immediate-Early Protein ICP27 of Herpes Simplex Virus", J. of Virology, Vol. 67, No. 1, PP. 613-616 (1993).
<i>L</i>	<i>AAE</i>	Watanabe et al. "Induction of Antibodies to a KV Region by Gene Immunization", J. of Immuno. Vol. 151, PP. 2871-2876 (1993).
<i>L</i>	<i>AAF</i>	Ellis et al. "New Vaccine Technologies", JAMA, Vol. 271, No. 12, PP. 929-931.
<i>L</i>	<i>AAG</i>	Ho et al. "Liposome formulated interleukin-2 as an adjuvant of recombinant HSV glycoprotein gD for the treatment of recurrent genital HSV-2 in guinea pigs", Vaccine, Vol. 10, Issue 4, PP. 209-213 (1992).
<i>L</i>	<i>AAH</i>	Friedman, "Progress Toward Human Gene Thereapy", Science, Vol. 259, PP. 1275-1281 (1989).
<i>L</i>	<i>AAI</i>	Edgington, "Turning on Tumor Fighting T-Cells", Bio/Technology, Vol. 11, Oct 1993, PP. 1117-1119 (1993).
<i>L</i>	<i>AAJ</i>	Manickan et al. "Protection against HSV infection by DNA vaccination: plasmid DNA encoding HSV-1 gB protects mice from HSV-1 zosteriform lesions", FASEB Jour. Vol. 9, No. 3 P. A207 and Exper. Biol. 95, Part 1, Atlanta GA, USA (Apr9-13) (1995).

Examiner
SignatureDate
Considered

6/24/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE**STATEMENT BY APPLICANT**

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	09/835,699
Filing Date	April 16, 2001
First Named Inventor	Armstrong, et al.
Group Art Unit	1631
Examiner Name	Martinell, James
Attorney Docket Number	19258CC

Sheet

4

of

4

OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
L	AAK	Ghiasi et al. "Vaccination of mice with herpes simplex virus type 1 glycoprotein-D DNA produces low levels of protection against lethal HSV-1 challenge", Antiviral Res. Vol. 28, No. 2, PP. 147-157 (1995).
L	AAL	Marwick, "Exciting Potential of DNA Vaccines Explored", JAMA, Vol. 273, No. 18, PP. 1403-1404 (1995).
L	AAM	Liu et al. "Immune responses and pre-clinical efficacy of DNA vaccines for viral diseases", Int. Pharm. J., Vol. 9, Suppl. 1, 10 (1995).
L	AAN	Shinya, "Recombinant DNA Integration with Herpes Simplex Gene...", Patent Abstract of Japan, Vol. 11, 332 (1987).
L	AAO	McClements et al. "Prevention of LETHAL HSV-2 Infection in Mice by Immunization with DNA encoding HSV-2 Glycoproteins, 20th Ann. Herpesvirus Workshop, Abs. #359, 1995.
L	AAP	McClements et al. "Immunization with DNA Vaccines Encoding GlcD or GlcB, alone or in combination, induces...", Proc. Natl. Acad. Sci., Vol. 93, PP. 11414-11420, (1996).
L	AAQ	Lasky et al. "DNA Sequence Analysis of the Type-Common Glycoprotein-D Genes of Herpes Simplex Virus Types 1 and 2". DNA, Volume 3, No. 1, PP. 23-29.

Examiner
SignatureDate
Considered

6/24/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.